这是一篇来自已证抗体库的有关
人类 PBRM1的综述，是根据16篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合PBRM1 抗体。
PBRM1 同义词: BAF180; PB1; protein polybromo-1; BRG1-associated factor 180; polybromo-1D
Bethyl
| 兔 多克隆 | | Bethyl PBRM1抗体（Bethyl Laboratories, A301-590A)被用于被用于免疫印迹在人类样品上 (图 2a). J Biol Chem (2018) ncbi |
| 兔 多克隆 | - 免疫印迹; 人类; 1:1000; 图 1-s1d
| Bethyl PBRM1抗体（Bethyl Laboratories, A301-591A)被用于被用于免疫印迹在人类样品上浓度为1:1000 (图 1-s1d). elife (2017) ncbi |
| 兔 多克隆 | - 免疫沉淀; 人类; 图 1
- 免疫印迹; 人类; 图 1
| Bethyl PBRM1抗体（Bethyl Laboratories, A301-591A)被用于被用于免疫沉淀在人类样品上 (图 1) 和 被用于免疫印迹在人类样品上 (图 1). PLoS ONE (2016) ncbi |
| 兔 多克隆 | - 染色质免疫沉淀
; 小鼠
- 免疫印迹; 小鼠; 1:500; 图 4a
| Bethyl PBRM1抗体（Bethyl Laboratories, A301-591A)被用于被用于染色质免疫沉淀
在小鼠样品上 和 被用于免疫印迹在小鼠样品上浓度为1:500 (图 4a). Oncotarget (2016) ncbi |
| 兔 多克隆 | - immunohistochemistry - free floating section; 人类; 1:250; 图 s3
| Bethyl PBRM1抗体（Bethyl Laboratories, A301-591A)被用于被用于immunohistochemistry - free floating section在人类样品上浓度为1:250 (图 s3). Mod Pathol (2016) ncbi |
| 兔 多克隆 | | Bethyl PBRM1抗体（Bethyl Laboratories, A301-591A)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图 3). J Med Genet (2015) ncbi |
| 兔 多克隆 | | Bethyl PBRM1抗体（Bethyl, A301-590A)被用于被用于免疫印迹在人类样品上 (图 6). PLoS Genet (2015) ncbi |
| 兔 多克隆 | - 免疫组化-石蜡切片; 人类; 1:250; 表 1
| Bethyl PBRM1抗体（Bethyl Laboratories, A301-591A)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:250 (表 1). Histopathology (2015) ncbi |
| 兔 多克隆 | | Bethyl PBRM1抗体（Bethyl, A301-591A)被用于被用于免疫组化在人类样品上浓度为1:250. Urol Oncol (2015) ncbi |
| 兔 多克隆 | | Bethyl PBRM1抗体（Bethyl Laboratory, A301-591A)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:250. Hum Pathol (2014) ncbi |
| 兔 多克隆 | | Bethyl PBRM1抗体（GE医疗保健, A301-590A)被用于被用于免疫印迹在人类样品上 (图 1a). Oncogene (2014) ncbi |
Novus Biologicals
| 兔 多克隆 | - 免疫组化; 人类; 图 1b
- 免疫印迹; 人类; 图 1a
| Novus Biologicals PBRM1抗体（Novus Biologicals, NB100-79833)被用于被用于免疫组化在人类样品上 (图 1b) 和 被用于免疫印迹在人类样品上 (图 1a). Oncogenesis (2017) ncbi |
赛默飞世尔
| 小鼠 单克隆 | | 赛默飞世尔 PBRM1抗体（life tech, 730027)被用于被用于免疫沉淀在人类样品上浓度为2 ug. Nat Methods (2015) ncbi |
默克密理博中国
| 兔 多克隆 | | 默克密理博中国 PBRM1抗体（Millipore, ABE70)被用于被用于免疫印迹在人类样品上浓度为1:500. DNA Repair (Amst) (2016) ncbi |
| 兔 多克隆 | | 默克密理博中国 PBRM1抗体（Millipore, ABE70)被用于被用于免疫沉淀在人类样品上. PLoS ONE (2012) ncbi |
西格玛奥德里奇
| 兔 多克隆 | - 免疫组化; 人类; 1:30; 图 4
- 免疫印迹; 人类; 图 1
| 西格玛奥德里奇 PBRM1抗体（Sigma, HPA015629)被用于被用于免疫组化在人类样品上浓度为1:30 (图 4) 和 被用于免疫印迹在人类样品上 (图 1). J Pathol (2015) ncbi |
Alpsoy A, Dykhuizen E. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes. J Biol Chem. 2018;293:3892-3903
pubmed 出版商 Kelso T, Porter D, Amaral M, Shokhirev M, Benner C, Hargreaves D. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. elife. 2017;6:
pubmed 出版商 Murakami A, Wang L, Kalhorn S, Schraml P, Rathmell W, Tan A,
et al. Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. Oncogenesis. 2017;6:e287
pubmed 出版商 Hopkins S, McGregor G, Murray J, Downs J, Savic V. Novel synthetic lethality screening method identifies TIP60-dependent radiation sensitivity in the absence of BAF180. DNA Repair (Amst). 2016;46:47-54
pubmed 出版商 Chowdhury B, Porter E, Stewart J, Ferreira C, Schipma M, Dykhuizen E. PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma. PLoS ONE. 2016;11:e0153718
pubmed 出版商 Lee H, Dai F, Zhuang L, Xiao Z, Kim J, Zhang Y,
et al. BAF180 regulates cellular senescence and hematopoietic stem cell homeostasis through p21. Oncotarget. 2016;7:19134-46
pubmed 出版商 Ho T, Kapur P, Joseph R, Serie D, Eckel Passow J, Tong P,
et al. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Mod Pathol. 2016;29:34-42
pubmed 出版商 Macher Goeppinger S, Keith M, Tagscherer K, Singer S, Winkler J, Hofmann T,
et al. PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas. J Pathol. 2015;237:460-71
pubmed 出版商 Marcon E, Jain H, Bhattacharya A, Guo H, Phanse S, Pu S,
et al. Assessment of a method to characterize antibody selectivity and specificity for use in immunoprecipitation. Nat Methods. 2015;12:725-31
pubmed 出版商 Benusiglio P, Couvé S, Gilbert Dussardier B, Deveaux S, Le Jeune H, Da Costa M,
et al. A germline mutation in PBRM1 predisposes to renal cell carcinoma. J Med Genet. 2015;52:426-30
pubmed 出版商 Ceballos Chávez M, Subtil RodrÃguez A, Giannopoulou E, Soronellas D, Vázquez Chávez E, Vicent G,
et al. The chromatin Remodeler CHD8 is required for activation of progesterone receptor-dependent enhancers. PLoS Genet. 2015;11:e1005174
pubmed 出版商 Rao Q, Xia Q, Wang Z, Li L, Shen Q, Shi S,
et al. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Histopathology. 2015;67:121-9
pubmed 出版商 Ho T, Kapur P, Joseph R, Serie D, Eckel Passow J, Parasramka M,
et al. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urol Oncol. 2015;33:23.e9-23.e14
pubmed 出版商 Li L, Fan X, Xia Q, Rao Q, Liu B, Yu B,
et al. Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis. Hum Pathol. 2014;45:2247-54
pubmed 出版商 Alfonso Pérez T, Domínguez Sánchez M, Garcia Dominguez M, Reyes J. Cytoplasmic interaction of the tumour suppressor protein hSNF5 with dynamin-2 controls endocytosis. Oncogene. 2014;33:3064-74
pubmed 出版商 Leung J, Nevins J. E2F6 associates with BRG1 in transcriptional regulation. PLoS ONE. 2012;7:e47967
pubmed 出版商
